A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Conatumumab (Primary) ; Ganitumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Cancer; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Amgen; NantCell
- 28 Nov 2017 Planned End Date changed from 25 Jan 2018 to 25 Jul 2018.
- 28 Nov 2017 Planned primary completion date changed from 25 Jan 2018 to 25 Jul 2018.
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 25 Jan 2018.